BridgeBio Pharma (BBIO) Expected to Announce Quarterly Earnings on Thursday

BridgeBio Pharma (NASDAQ:BBIO) will likely be announcing its Q3 2026 results after the market closes on Thursday, October 29th. Analysts expect the company to announce earnings of ($0.5423) per share and revenue of $293.47 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, October 29, 2026 at 4:30 PM ET.

BridgeBio Pharma (NASDAQ:BBIO) last issued its earnings results on Monday, August 10th. The company reported ($0.78) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.20). The company had revenue of $243.68 million during the quarter, compared to analyst estimates of $220.91 million. BridgeBio Pharma’s quarterly revenue was up 120.4% compared to the same quarter last year. During the same period last year, the firm earned ($0.95) earnings per share. On average, analysts expect BridgeBio Pharma to post ($2.64) EPS for the current fiscal year and ($0.72) EPS for the next fiscal year.

BridgeBio Pharma Trading Down 0.6%

Shares of NASDAQ:BBIO opened at $68.15 on Tuesday. The business’s 50 day simple moving average is $71.38 and its two-hundred day simple moving average is $72.95. BridgeBio Pharma has a 52-week low of $56.74 and a 52-week high of $93.42.

Insider Activity

In related news, CEO Neil Kumar sold 10,000 shares of the firm’s stock in a transaction dated Thursday, September 17th. The shares were sold at an average price of $69.08, for a total value of $690,800.00. Following the transaction, the chief executive officer owned 495,686 shares of the company’s stock, valued at approximately $34,241,988.88. This trade represents a 1.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Maricel Apuli sold 2,000 shares of BridgeBio Pharma stock in a transaction dated Thursday, July 30th. The shares were sold at an average price of $80.06, for a total value of $160,120.00. Following the transaction, the chief accounting officer owned 127,401 shares of the company’s stock, valued at $10,199,724.06. This trade represents a 1.55% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 56,980 shares of company stock valued at $4,578,119. 14.23% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

BBIO has been the subject of a number of research reports. Mizuho boosted their price objective on BridgeBio Pharma from $96.00 to $110.00 and gave the company an “outperform” rating in a report on Tuesday, September 1st. HC Wainwright reaffirmed a “buy” rating on shares of BridgeBio Pharma in a research report on Tuesday, October 6th. Bank of America increased their target price on BridgeBio Pharma from $101.00 to $104.00 and gave the stock a “buy” rating in a report on Tuesday, August 11th. Cantor Fitzgerald reiterated an “overweight” rating on shares of BridgeBio Pharma in a report on Monday, October 5th. Finally, TD Cowen reissued a “buy” rating on shares of BridgeBio Pharma in a research report on Monday, October 5th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, BridgeBio Pharma has a consensus rating of “Moderate Buy” and a consensus target price of $104.40.

BridgeBio Pharma Company Profile

BridgeBio Pharma, Inc is a biopharmaceutical company focused on discovering, developing and commercializing medicines for genetically driven diseases. The company operates through a portfolio of subsidiary and affiliated biotechnology businesses, with research programs spanning rare diseases, oncology, cardiology and other conditions linked to underlying genetic or molecular causes.

BridgeBio’s portfolio includes therapies designed to address the root mechanisms of disease rather than primarily treating symptoms.